Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations

BACKGROUND: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk of developing adverse reactions and treatment f...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanković, Biljana, Kotur, Nikola, Gašić, Vladimir, Klaassen, Kristel, Ristivojević, Bojan, Stojiljković, Maja, Pavlović, Sonja, Zukić, Branka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Medical Biochemists of Serbia, Belgrade 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710379/
https://www.ncbi.nlm.nih.gov/pubmed/33312066
http://dx.doi.org/10.5937/jomb0-26725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710379/
https://www.ncbi.nlm.nih.gov/pubmed/33312066
http://dx.doi.org/10.5937/jomb0-26725

Ejemplares similares